|hotly discussed information exclusive information hot topic Hot info frontline information
According to the Star of Securities,Current Affairs Jinsbo Bio (832982) issued an announcement on December 4, 2023, saying that the company was investigated on November 30, 2023., Xiangcai Securities, Shen Wanhongyuan, Castrol Fund, Cinda Securities, everyone's assets, CITIC Construction Investment Fund, Xingye Fund, China Life Life Pension Insurance Co., Ltd., Shanghai Securities and Huajin Securities participated.
The specific content is as follows:
Q: The company's product sales plan in 2024?
Answer: In 2024, the company will continue to launch new products and open up sales channels to promote performance growth.The company's 2024 budget is currently prepared.
Question: How much is the company's single -component medical device product sales in 2023?
Answer: At present, the sales of single -ingredients medical device products are all normal. For specific sales data, please pay attention to the regular reports disclosed by the company.
Q: Ask the company's main ingredient cosmetics to sell the main sales channels and sales in 2023?
Answer: The company's single component cosmetics are mainly sold online channels. For specific sales data, please pay attention to the regular reports disclosed by the company.
Question: Does L'Oreal currently have products from purchasing companies?
Answer: At present, L'Oreal has the raw material product of the company.
Question: Will the company consider using crosslinkers in the reorganized humanized collagen products developed in the future?
Answer: Among the medical devices developed and sold by the company, the company's independently developed reorganized humanized collagen single -material medical device is the main medical device, which is more complete and safer to degrade. Therefore, the use of cross -linking agents is not the current direction of the company.
Question: After the company's 4mg specifications, type III human -source collagen frozen and dry fibers have changed sharply after the factory price has occurred?
Answer: The company's 4mg specifications of type III human source collagen frozen and dry fibers have not changed sharply after the factory price has occurred.
Question 7. The company's reorganization of type III humanized collagen frozen -drying fiber products mainly sell for medical cosmetic institutions.
The company's reorganization of type III human -source collagen frozen and dry fiber products are mainly sold in private medical cosmetic institutions. In addition, a small number of them are sold in public hospitals.
Q: Is the company's current reorganized human -based collagen raw material products mainly cosmetics or medical grade?
Answer: At present, the company's reorganized human -owned collagen raw material products are mainly cosmetics.
The main business of Jinsbo Biological (832982): Basic research and industrialization of original functional protein involves two major technological areas of antiviral and humanized collagen.
The third quarter report of Jinsbo Biological in 2023 shows that the company's main revenue of 517 million yuan, an increase of 105.64%year -on -year; net profit of returning home was 19.2 million yuan, an increase of 173.75%year -on -year; the non -net profit was 184 million yuan, a year -on -year increase of 179.77%;In the third quarter of the year, the company's main revenue in a single quarter was 201 million yuan, an increase of 106.43%year -on -year; net profit attributable to mothers in the single quarter was 82.8427 million yuan, an increase of 168.75%year -on -year; the non -net profit of non -net profit in the single quarter was 80.12 million yuan, a year -on -year increase of 173.58%;The debt ratio was 37.75%, the investment income was 176,700 yuan, the financial expenses were 8.3826 million yuan, and the gross profit margin was 89.97%.
The stock has not been rated in the last 90 days.Frequent financing and securities and financing data shows that the stock net inflow of financing in the past three months was 56.6042 million, and the increase in financing balances increased; the net inflow of financing of securities was 0.0, and the balance of margin financing increased.